GlassScriptPhysician profile
Kyle A Burton
NPI 1730543455
$2,932.98
in general payments reported to CMS, 2019-2025
29 companies · $804 in 2025
The $804 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $174 · 2021: $13.91 · 2022: $63.75 · 2023: $224 · 2024: $1,027 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.01 |
| Education | $165.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.13 | 2019-2025 | Skyrizi |
| Galderma Laboratories, L.P. | $338.32 | 2019-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $280.99 | 2024-2025 | Dupixent |
| Genzyme Corporation | $237.36 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $230.73 | 2019-2024 | |
| Janssen Biotech, INC. | $218.02 | 2023-2025 | Tremfya, Stelara, Simponi |
| Merz North America, INC. | $175.06 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $156.68 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| Sun Pharmaceutical Industries INC. | $116.90 | 2024-2025 | |
| Lilly USA, LLC | $112.74 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Sanofi-Aventis U.S. LLC | $87.61 | 2019 | |
| Leo Pharma INC. | $69.73 | 2022-2025 | Adbry |
| Tactile Systems Technology INC | $63.32 | 2020 | |
| Amgen INC. | $61.32 | 2023-2025 | Otezla |
| Almirall LLC | $54.13 | 2024 | Seysara |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.97 | 2024-2025 | |
| Incyte Corporation | $46.96 | 2024 | Opzelura |
| Revance Therapeutics, INC. | $42.06 | 2024 | Daxxify |
| Ucb, INC. | $36.91 | 2024 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.26 | 2025 | Spevigo |
| Strata Skin Sciences, INC. | $29.00 | 2025 | Xtrac |
| Kyowa Kirin, INC. | $25.24 | 2025 | |
| Boston Scientific Corporation | $24.52 | 2025 | Obsidio |
| E.R. Squibb & Sons, L.L.C. | $23.65 | 2024 | Sotyktu |
| Organon LLC | $19.78 | 2025 | Vtama |
| Convatec INC. | $16.91 | 2024 | |
| Arcutis Biotherapeutics, INC. | $14.60 | 2023 | |
| Allergan, INC. | $13.91 | 2021 | |
| Kerecis Limited | $11.17 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.